Advertisement

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial

  • Akihiro Tomida
  • Keisuke UeharaEmail author
  • Kazuhiro Hiramatsu
  • Atsuyuki Maeda
  • Eiji Sakamoto
  • Yoshito Okada
  • Yasuhiro Kurumiya
  • Goro Nakayama
  • Masanao Nakamura
  • Toshisada Aiba
  • Masato Nagino
  • Of the Nagoya Surgical Oncology Group
Original Article
  • 139 Downloads

Abstract

Background

Neoadjuvant chemotherapy (NAC) alone for locally advanced rectal cancer (LARC) remains an experimental treatment, and the efficacy in terms of long-term outcome has not been fully elucidated. The N-SOG 03 trial examined the safety and efficacy of neoadjuvant CAPOX and bevacizumab (Bev) without radiotherapy in patients with poor-risk LARC.

Methods

Thirty-two patients with MRI-defined LARC received neoadjuvant CAPOX and Bev followed by curative resection between 2010 and 2011. The overall survival (OS), progression-free survival (PFS), and local-relapse rate (LRR) were calculated using the Kaplan–Meier method, and the risk factors were evaluated by multivariate analysis using the Cox proportional hazard models. This trial is registered with UMIN, number 000003507.

Results

In the entire cohort, the 5-year OS was 81.3%. Because of disease progression during chemotherapy, 3 patients ultimately did not undergo curative surgery. As a result, 29 patients underwent R0/1 resection. Among these 29 patients, the 5-year OS, PFS, and LRR were 89.7%, 72.4% and 13.9%, respectively. In multivariate analysis, cT4b tumor was an independent poor prognostic factor for OS and LRR, and ypT4b tumor and absence of N down-staging were independent poor prognostic factors for PFS.

Conclusions

Patients with cT4b tumor were not suitable for NAC alone. However, the long-term outcomes of the other patients were satisfactory, and NAC alone might be an option for treatment of LARC. N down-staging was likely to bring favorable PFS, even in patients with cStage III.

Keywords

Rectal cancer Neoadjuvant chemotherapy Phase II trial Outcome 

Notes

Acknowledgements

We are grateful to many other members of the Nagoya Surgical Oncology Group during the study.

Funding

We have no funding support.

Compliance with ethical standards

Conflict of interest

All authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646CrossRefGoogle Scholar
  2. 2.
    Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701CrossRefGoogle Scholar
  3. 3.
    van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582CrossRefGoogle Scholar
  4. 4.
    Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefGoogle Scholar
  5. 5.
    Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933CrossRefGoogle Scholar
  6. 6.
    Gérard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30:4558–4565CrossRefGoogle Scholar
  7. 7.
    O’Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 32:1927–1934CrossRefGoogle Scholar
  8. 8.
    Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989CrossRefGoogle Scholar
  9. 9.
    Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722–1728CrossRefGoogle Scholar
  10. 10.
    Bujko K, Wyrwicz L, Rutkowski A et al (2016) Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27:834–842CrossRefGoogle Scholar
  11. 11.
    Franke AJ, Parekh H, Starr JS et al (2018) Total neoadjuvant therapy: a shifting paradigm in locally advanced rectal cancer management. Clin Colorectal Cancer 17:1–12CrossRefGoogle Scholar
  12. 12.
    Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32:513–518CrossRefGoogle Scholar
  13. 13.
    Patel UB, Brown G, Machado I et al (2017) MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol 28:344–353CrossRefGoogle Scholar
  14. 14.
    Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefGoogle Scholar
  15. 15.
    Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRefGoogle Scholar
  16. 16.
    Uehara K, Hiramatsu K, Maeda A et al (2013) Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol 43:964–971CrossRefGoogle Scholar
  17. 17.
    Hasegawa J, Nishimura J, Mizushima T et al (2014) Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol 73:1079–1087CrossRefGoogle Scholar
  18. 18.
    Kamiya T, Uehara K, Nakayama G et al (2016) Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. Eur J Surg Oncol 42:829–835CrossRefGoogle Scholar
  19. 19.
    Koike J, Funahashi K, Yoshimatsu K et al (2017) Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. Cancer Chemother Pharmacol 79:519–525CrossRefGoogle Scholar
  20. 20.
    Hasegawa S, Goto S, Matsumoto T et al (2017) A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol 24:3587–3595CrossRefGoogle Scholar
  21. 21.
    Japanese Society for Cancer of the Colon and Rectum (2009) Japanese classification of colorectal carcinoma, 2nd English edition. Kanehara, TokyoGoogle Scholar
  22. 22.
    Green SJ, Dahlberg S (1992) Planned versus attained design in phase II clinical trials. Stat Med 11:853–862CrossRefGoogle Scholar
  23. 23.
    Deng Y, Chi P, Lan P et al (2016) Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol 34:3300–3307CrossRefGoogle Scholar
  24. 24.
    Bosset JF, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123CrossRefGoogle Scholar
  25. 25.
    Ishiguro S, Akasu T, Fujita S et al (2009) Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. Surgery 145:189–195CrossRefGoogle Scholar
  26. 26.
    Nakamura T, Yamashita K, Sato T et al (2014) Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys 89:547–555CrossRefGoogle Scholar
  27. 27.
    Hong YS, Nam BH, Kim KP et al (2014) Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2018

Authors and Affiliations

  • Akihiro Tomida
    • 1
  • Keisuke Uehara
    • 1
    Email author
  • Kazuhiro Hiramatsu
    • 2
  • Atsuyuki Maeda
    • 3
  • Eiji Sakamoto
    • 4
  • Yoshito Okada
    • 5
  • Yasuhiro Kurumiya
    • 6
  • Goro Nakayama
    • 7
  • Masanao Nakamura
    • 8
  • Toshisada Aiba
    • 1
  • Masato Nagino
    • 1
  • Of the Nagoya Surgical Oncology Group
  1. 1.Division of Surgical Oncology, Department of SurgeryNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of SurgeryToyohashi Municipal HospitalToyohashiJapan
  3. 3.Department of SurgeryOgaki Municipal HospitalGifuJapan
  4. 4.Department of SurgeryNagoya Daini Red Cross HospitalNagoyaJapan
  5. 5.Department of SurgeryHanda City HospitalHandaJapan
  6. 6.Department of SurgeryToyota Kosei HospitalToyotaJapan
  7. 7.Department of Gastroenterological SurgeryNagoya University Graduate School of MedicineNagoyaJapan
  8. 8.Department of GastroenterologyNagoya University Graduate School of MedicineNagoyaJapan

Personalised recommendations